SARS-CoV-2 (COVID-19) infection in pregnant women: characterization of symptoms and syndromes predictive of disease and severity through real-time, remote participatory epidemiology.

SARS-CoV-2 risk factors SARS-CoV-2 severity anosmia citizen science community SARS-CoV-2 symptoms digital health pregnancy syndromic surveillance

Journal

medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986

Informations de publication

Date de publication:
14 Oct 2020
Historique:
pubmed: 26 8 2020
medline: 26 8 2020
entrez: 26 8 2020
Statut: epublish

Résumé

To test whether pregnant and non-pregnant women differ in COVID-19 symptom profile and severity. To extend previous investigations on hospitalized pregnant women to those who did not require hospitalization. Observational study prospectively collecting longitudinal (smartphone application interface) and cross-sectional (web-based survey) data. Community-based self-participatory citizen surveillance in the United Kingdom, Sweden and the United States of America. Two female community-based cohorts aged 18-44 years. The discovery cohort was drawn from 1,170,315 UK, Sweden and USA women (79 pregnant tested positive) who self-reported status and symptoms longitudinally via smartphone. The replication cohort included 1,344,966 USA women (134 pregnant tested positive) who provided cross-sectional self-reports. Pregnant and non-pregnant were compared for frequencies of symptoms and events, including SARS-CoV-2 testing and hospitalization rates. Multivariable regression was used to investigate symptoms severity and comorbidity effects. Pregnant and non-pregnant women positive for SARS-CoV-2 infection were not different in syndromic severity. Pregnant were more likely to have received testing than non-pregnant, despite reporting fewer symptoms. Pre-existing lung disease was most closely associated with the syndromic severity in pregnant hospitalized women. Heart and kidney diseases and diabetes increased risk. The most frequent symptoms among all non-hospitalized women were anosmia [63% pregnant, 92% non-pregnant] and headache [72%, 62%]. Cardiopulmonary symptoms, including persistent cough [80%] and chest pain [73%], were more frequent among pregnant women who were hospitalized. Symptom characteristics and severity were comparable among pregnant and non-pregnant women, except for gastrointestinal symptoms. Consistent with observations in non-pregnant populations, lung disease and diabetes were associated with increased risk of more severe SARS-CoV-2 infection during pregnancy.

Identifiants

pubmed: 32839787
doi: 10.1101/2020.08.17.20161760
pmc: PMC7444306
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK120899
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Declaration of interest EM, CMA, WM, JB, MFG, MM have no conflict of interest. ATC previously served as an investigator on a clinical trial of diet and lifestyle using a separate mobile application that was supported by Zoe Global Ltd.

Auteurs

Erika Molteni (E)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.

Christina M Astley (CM)

Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Wenjie Ma (W)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.

Carole H Sudre (CH)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.

Laura A Magee (LA)

Department of Women and Children's Health, School of Life Course Sciences and the Institute of Women and Children's Health, King's College London, London, United Kingdom.

Benjamin Murray (B)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.

Tove Fall (T)

Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Sweden.

Maria F Gomez (MF)

Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenströms gata 35, SE-21428, Malmo, Sweden.

Neli Tsereteli (N)

Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenströms gata 35, SE-21428, Malmo, Sweden.

Paul W Franks (PW)

Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenströms gata 35, SE-21428, Malmo, Sweden.

John S Brownstein (JS)

Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.

Richard Davies (R)

Zoe Global Limited, London, United Kingdom.

Jonathan Wolf (J)

Zoe Global Limited, London, United Kingdom.

Tim D Spector (TD)

Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom.

Sebastien Ourselin (S)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.

Claire J Steves (CJ)

Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom.

Andrew T Chan (AT)

Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA.

Marc Modat (M)

School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom.

Classifications MeSH